Skip to content Skip to footer
For most commuters hustling through Boston’s MBTA tunnels, Chicago’s labyrinthine corridors, or the glassy speedways of Orlando’s Brightline, digestive worries might seem like yesterday’s lunch. Yet, November 2025 finds a new contender vying for attention amid the ads for luxury watches and…
JFrog’s (FROG) third-quarter 2025 performance was anything but amphibious—unless “leaping” counts. The company vaulted past Wall Street forecasts, croaking out revenue of $139.6 million, soaring 26% year-over-year and leaving analysts' modest predictions somewhere in the lily pads. Investors had reason to rejoice;…
Eupraxia Pharmaceuticals (EPRX) delivered an impressive third quarter for 2025, underpinned by breakthrough clinical data, robust financial positioning, and a clearer trajectory toward commercial success. The company’s RESOLVE trial in eosinophilic esophagitis (EoE) demonstrated sustained clinical remission and long-lasting improvements in tissue…